Table 1.
Baseline clinical characteristics in the two cohorts.
Figure 1.
Association of MBL (panels A–B), ficolin-2 (C–D) and ficolin-3 (E–F) levels with severity of CHF.
P values of non-parametric Kruskall-Wallis test are indicated across NYHA class groups, stars indicate results of Dunnet’s post hoc test (*p<0.05, **p<0.01; as compared to NYHA I on panel E and NYHA II on panel F). Medians, 25 and 75 percentiles and ranges are indicated on logarithmic scales.
Figure 2.
Univariate correlation of ficolin-3 levels with NT-proBNP (A and B) and complement C3 (C and D).
Pearson’s correlation coefficients and p values are indicated.
Table 2.
Baseline clinical characteristics according to ficolin-3 levels (median, IQ range, or n (%)).
Figure 3.
Kaplan-Meier plot of baseline ficolin-3 levels (<15.0 µg/ml, thick line and > = 15.0 µg/ml, thin line) and long term survival (all-cause mortality) in patients with CHF.
Log-rank test for the Hungarian cohort (panel A) and for the Norwegian cohort (panel B) is indicated.
Table 3.
Results of multivariable Cox proportional-hazards regression analyzing effects of ficolin-3 for all-cause mortality.